Glofitamab API is a high-quality recombinant CD20×CD3 bispecific monoclonal antibody developed for the treatment of relapsed or refractory B-cell lymphomas, including Diffuse Large B-Cell Lymphoma (DLBCL). It simultaneously binds to CD20 on malignant B cells and CD3 on T cells, bringing immune cells into close proximity with tumor cells to promote targeted T-cell-mediated destruction.
Unlike conventional monoclonal antibodies, Glofitamab utilizes a bispecific antibody platform to deliver highly selective immune activation against cancer cells while minimizing damage to healthy tissues. It represents a significant advancement in immuno-oncology and targeted cancer therapy.
Swapnroop Drugs and Pharmaceuticals manufactures premium-quality Glofitamab API under stringent WHO-GMP manufacturing standards. Each batch undergoes rigorous quality testing for purity, biological activity, sterility, and stability. Complete regulatory documentation including CoA, MSDS, and technical specifications is available for global pharmaceutical and biotechnology companies.
Glofitamab API is supplied in validated sterile pharmaceutical packaging suitable for global pharmaceutical manufacturing.
Available packaging options include:
Each shipment includes:
Glofitamab API is used in immunotherapy for the treatment of relapsed or refractory B-cell lymphomas, including Diffuse Large B-Cell Lymphoma (DLBCL).
It is a bispecific antibody that binds both CD20 on B cells and CD3 on T cells, enabling targeted T-cell-mediated destruction of malignant B cells.
It belongs to the CD20×CD3 Bispecific Monoclonal Antibody class of immuno-oncology drugs.
Yes. We provide CoA, MSDS, technical specifications, stability data, and complete regulatory documentation.
Yes. We offer commercial quantities with worldwide export support.
Get Bulk Quote via WhatsApp